Soluble interleukin-2 receptor α and interleukin-2 serum levels in patients with basal cell carcinoma

Michal Sobjanek; Ewa Bien; Monika Zablotna; Malgorzata Sokolowska-Wojdylo; Monika Sikorska; Magdalena Lange; Roman Nowicki

doi:10.5114/pdia.2015.55177

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2016
vol. 33

Send email

Copy url:

abstract:

Original paper

Soluble interleukin-2 receptor α and interleukin-2 serum levels in patients with basal cell carcinoma

Michal Sobjanek

,

Ewa Bien

,

Monika Zablotna

,

Malgorzata Sokolowska-Wojdylo

,

Monika Sikorska

,

Magdalena Lange

,

Roman Nowicki

Adv Dermatol Allergol 2016; XXXIII (4): 263–268

DOI: https://doi.org/10.5114/pdia.2015.55177

Online publish date: 2016/08/16

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Sobjanek M, Bien E, Zablotna M, et al. Soluble interleukin-2 receptor α and interleukin-2 serum levels in patients with basal cell carcinoma. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2016;33(4):263-268. doi:10.5114/pdia.2015.55177.

APA

Sobjanek, M., Bien, E., Zablotna, M., Sokolowska-Wojdylo, M., Sikorska, M.,  & Lange, M. et al. (2016). Soluble interleukin-2 receptor α and interleukin-2 serum levels in patients with basal cell carcinoma. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 33(4), 263-268. https://doi.org/10.5114/pdia.2015.55177

Chicago

Sobjanek, Michal, Ewa Bien, Monika Zablotna, Malgorzata Sokolowska-Wojdylo, Monika Sikorska, Magdalena Lange,  and Roman Nowicki. 2016. "Soluble interleukin-2 receptor α and interleukin-2 serum levels in patients with basal cell carcinoma". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 33 (4): 263-268. doi:10.5114/pdia.2015.55177.

Harvard

Sobjanek, M., Bien, E., Zablotna, M., Sokolowska-Wojdylo, M., Sikorska, M., Lange, M.,  and Nowicki, R. (2016). Soluble interleukin-2 receptor α and interleukin-2 serum levels in patients with basal cell carcinoma. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 33(4), pp.263-268. https://doi.org/10.5114/pdia.2015.55177

MLA

Sobjanek, Michal et al. "Soluble interleukin-2 receptor α and interleukin-2 serum levels in patients with basal cell carcinoma." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 33, no. 4, 2016, pp. 263-268. doi:10.5114/pdia.2015.55177.

Vancouver

Sobjanek M, Bien E, Zablotna M, Sokolowska-Wojdylo M, Sikorska M, Lange M et al. Soluble interleukin-2 receptor α and interleukin-2 serum levels in patients with basal cell carcinoma. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2016;33(4):263-268. doi:10.5114/pdia.2015.55177.

Introduction: Basal cell carcinoma (BCC) is an immunogenic neoplasm and the imbalance in Th1/Th2 cytokines expression seems to play the major role in pathogenesis and clinical behaviour of the tumour.

Aim: To investigate the association of soluble interleukin 2α receptor (sIL-2Rα) and interleukin-2 (IL-2) serum concentrations with BCC.

Material and methods: The study involved 110 individuals with BCC and 60 healthy age- and sex-matched volunteers. Serum levels of sIL-2Rα and IL-2 were measured using ELISA test.

Results: We found significantly (p = 0.027) increased sIL-2Rα serum levels in BCC patients, in comparison to healthy controls. Statistically (p = 0.04) higher sIL-2Rα levels were observed in patients with more advanced tumours. Serum levels of sIL-2Rα showed a significant linear (r = 0.24, p = 0.018) correlation with tumour size. The average IL-2 serum levels in BCC patients were statistically (p = 0.039) decreased compared to controls. Significantly (p = 0.0454) lower median IL-2 levels were observed in patients with more advanced tumours. A negative correlation between sIL-2Rα and IL-2 serum concentrations was revealed (r = –0.22; p = 0.027).

Conclusions: Our results testify to the importance of the IL-2/sIL-2Rα signalling pathway in pathogenesis of BCC, suggesting that IL-2 and sIL-2Rα might be considered as potential markers of disease and targets for immunotherapy in BCC patients.

keywords:

Soluble interleukin-2 receptor α and interleukin-2 serum levels in patients with basal cell carcinoma

Michal Sobjanek , Ewa Bien , Monika Zablotna , Malgorzata Sokolowska-Wojdylo , Monika Sikorska , Magdalena Lange , Roman Nowicki

basal cell carcinoma, soluble interleukin-2 receptor α, interleukin-2, sIL-2Rα, IL-2

Michal Sobjanek

,

Ewa Bien

,

Monika Zablotna

,

Malgorzata Sokolowska-Wojdylo

,

Monika Sikorska

,

Magdalena Lange

,

Roman Nowicki